Search EN menu en EIB GROUP CLIENT PORTAL
Close EIB GROUP CLIENT PORTAL
Search
Search
Results
Top 5 search results See all results Advanced search
Top searches
    Most visited pages

        DEBRECEN PHARMA R&D RSFF

        Signature(s)

        Amount
        € 100,000,000
        Countries
        Sector(s)
        Hungary : € 100,000,000
        Industry : € 100,000,000
        Signature date(s)
        24/09/2009 : € 100,000,000

        Summary sheet

        Release date
        3 March 2009
        Status
        Reference
        Signed | 24/09/2009
        20080302
        Project name
        Promoter - financial intermediary
        Debrecen Pharma R&D (RSFF)

        The promoter is one of the top 20 pharmaceutical companies in the world and the largest generic pharmaceutical company.

        Proposed EIB finance (Approximate amount)
        Total cost (Approximate amount)
        EUR 100 million.
        EUR 200 million.
        Location
        Sector(s)
        Description
        Objectives

        The project concerns financing the R&D for new Active Pharmaceutical Ingredients (APIs), innovative drug compounds and new generic drugs located in Debrecen, Gödöllö and Sajobabony, as well as two related capital expenditure investments in R&D Centres in Debrecen and Gödöllö.

        The aim of the first, R&D part of the project is the commercialisation of more than 30 new generic compounds up to 2013. The purpose of the capital expenditure investments is to increase the existing R&D infrastructure.

        Environmental aspects
        Procurement

        Installations for the R&D Centre in Debrecen will fall under Annex II of the EIA Directive 85/337/EEC, amended by Directives 97/11/EC and 2003/35/EC. Whether the competent authorities have required an EIA or not will be verified during appraisal, as well as any actual/possible significant impacts on protected flora and fauna (Habitats and Birds Directives). Compliance of R&D activities with relevant EU legislation in regards to animal testing, clinical trials, etc. will be verified during appraisal.

        The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives 2004/18/EC. The promoter carries out competitive international consultations among potential suppliers for goods and services, which is standard practice for this industry.

        Disclaimer

        Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
        They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

        General enquiries and comments

        The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
        Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
        Alternatively, the EIB can be contacted through its external offices.
        Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

        Media enquiries

        Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

        Complaints mechanism

        Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

        Zero tolerance against fraud and corruption

        The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Investigations Division. All reports will be treated as strictly confidential and handled in line with EIB investigation procedures and the EIB Group Anti-Fraud Policy.

        Related publications